Blueprint Medicines Corp (BPMC) Insider Trading
- $348,278.00
- $154,115,495.49
- May 2, 2024
- Jeffrey W Albers
| Trader Name | Date | Title | Amount | Price | Type | Total Value |
|---|---|---|---|---|---|---|
| July 19, 2019 | Insider | 115 | $100.00 | Sell | $11,500.00 | |
| July 16, 2019 | COO | 1,571 | $95.47 | Sell | $149,983.37 | |
| July 15, 2019 | Insider | 830 | $94.98 | Sell | $78,833.40 | |
| July 8, 2019 | Insider | 10,000 | $93.88 | Sell | $938,800.00 | |
| June 27, 2019 | Director | 21,818 | $92.01 | Sell | $2,007,474.18 | |
| June 20, 2019 | Director | 11,818 | $95.15 | Sell | $1,124,482.70 | |
| June 17, 2019 | CEO | 5,000 | $99.06 | Sell | $495,300.00 | |
| June 17, 2019 | COO | 11,952 | $96.46 | Sell | $1,152,889.92 | |
| June 17, 2019 | Director | 1,136 | $98.50 | Sell | $111,896.00 | |
| June 17, 2019 | Insider | 1,405 | $98.22 | Sell | $137,999.10 | |
| June 13, 2019 | Insider | 2,733 | $88.04 | Sell | $240,613.32 | |
| June 12, 2019 | CEO | 20,000 | $84.75 | Sell | $1,695,000.00 | |
| June 12, 2019 | Director | 25,000 | $84.77 | Sell | $2,119,250.00 | |
| March 15, 2019 | Insider | 415 | $85.55 | Sell | $35,503.25 | |
| March 15, 2019 | CEO | 20,000 | $86.39 | Sell | $1,727,800.00 | |
| March 4, 2019 | Insider | 2,300 | $84.66 | Sell | $194,718.00 | |
| March 1, 2019 | COO | 21,644 | $85.05 | Sell | $1,840,822.20 | |
| Nov. 5, 2018 | CEO | 20,000 | $63.49 | Sell | $1,269,800.00 | |
| Sept. 17, 2018 | Insider | 2,300 | $70.47 | Sell | $162,081.00 | |
| Aug. 6, 2018 | CEO | 20,000 | $70.59 | Sell | $1,411,800.00 | |
| May 7, 2018 | CEO | 20,000 | $78.90 | Sell | $1,578,000.00 | |
| March 19, 2018 | Director | 5,492 | $100.09 | Sell | $549,694.28 | |
| March 15, 2018 | Insider | 2,300 | $100.07 | Sell | $230,161.00 | |
| March 2, 2018 | CEO | 20,000 | $92.57 | Sell | $1,851,400.00 | |
| Feb. 28, 2018 | Director | 25,000 | $87.89 | Sell | $2,197,250.00 | |
| Feb. 14, 2018 | Director | 12,500 | $80.42 | Sell | $1,005,250.00 | |
| Feb. 12, 2018 | Director | 17,500 | $74.84 | Sell | $1,309,700.00 | |
| Feb. 12, 2018 | Insider | 6,775 | $74.93 | Sell | $507,650.75 | |
| Nov. 21, 2017 | Insider | 18,334 | $65.45 | Sell | $1,199,960.30 | |
| Nov. 15, 2017 | Director | 5,000 | $63.38 | Sell | $316,900.00 | |
| Nov. 6, 2017 | CEO | 30,000 | $70.31 | Sell | $2,109,300.00 | |
| Nov. 6, 2017 | Insider | 5,000 | $70.40 | Sell | $352,000.00 | |
| Oct. 5, 2017 | Insider | 5,449 | $66.44 | Sell | $362,031.56 | |
| Sept. 18, 2017 | Director | 2,500 | $60.00 | Sell | $150,000.00 | |
| Sept. 18, 2017 | Insider | 6,356 | $60.03 | Sell | $381,550.68 | |
| Aug. 9, 2017 | Insider | 5,000 | $48.60 | Sell | $243,000.00 | |
| Aug. 8, 2017 | CEO | 30,000 | $49.62 | Sell | $1,488,600.00 | |
| Aug. 7, 2017 | CEO | 20,000 | $49.08 | Sell | $981,600.00 | |
| July 5, 2017 | Insider | 7,265 | $54.66 | Sell | $397,104.90 | |
| July 5, 2017 | Director | 7,500 | $55.06 | Sell | $412,950.00 | |
| June 28, 2017 | Director | 32,500 | $50.28 | Sell | $1,634,100.00 | |
| June 28, 2017 | CEO | 20,000 | $50.47 | Sell | $1,009,400.00 | |
| June 28, 2017 | Insider | 6,357 | $50.00 | Sell | $317,850.00 | |
| March 16, 2017 | Major Shareholder | 30,000 | $40.88 | Sell | $1,226,400.00 | |
| Feb. 7, 2017 | Major Shareholder | 1,000,000 | $35.28 | Sell | $35,280,000.00 | |
| Dec. 19, 2016 | Major Shareholder | 106,489 | $28.19 | Sell | $3,001,924.91 | |
| Dec. 1, 2016 | Director | 200 | $30.02 | Sell | $6,004.00 | |
| Oct. 13, 2016 | Director | 21,800 | $30.02 | Sell | $654,436.00 | |
| Aug. 8, 2016 | CEO | 17,000 | $22.86 | Sell | $388,620.00 | |
| June 3, 2016 | CEO | 17,000 | $20.03 | Sell | $340,510.00 |
Insiders are both buying and selling Blueprint Medicines Corp stock.
The insider traders at Blueprint Medicines Corp are: Jeffrey W Albers, Ariel Hurley, Kate Haviland, Daniel Lynch, Christopher K Murray, Marion Dorsch, George Demetri, Nicholas Lydon, Anthony L Boral, Tracey L Mccain, Fmr Llc, L. Becker Hewes, Michael Landsittel, Christina Rossi, Christoph Lengauer, Mark Alan Goldberg, Fouad Namouni, Debra Durso-Bumpus, Charles A Rowland Jr, Percy H Carter, Alexis Borisy, Rock Ventures Ii L.P. Third, Kevin P. Starr, Lonnel Coats, and Mark J Levin
The most active insider trader at Blueprint Medicines Corp is Jeffrey W Albers with 38 trades.
Rock Ventures Ii L.P. Third has sold the most Blueprint Medicines Corp stock with a total value of $70,560,000.00.
Mark Alan Goldberg has bought the most Blueprint Medicines Corp stock with a total value of $599,800.00.
The most recent insider trade for Blueprint Medicines Corp was on May 2, 2024.
The single biggest insider buy for Blueprint Medicines Corp was from Mark Alan Goldberg with a total value of $299,900.00 on March 3, 2022.
The single biggest insider sell for Blueprint Medicines Corp was from Rock Ventures Ii L.P. Third with a total value of $35,280,000.00 on Feb. 7, 2017.